Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2016-05-10
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
NCT06735001
Effect of Ischemic Preconditioning on Atrial Fibrillation After Electrocardioversion
NCT05342220
Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion
NCT03346863
Long-term Outcome Following Concomitant Surgical Ablation for Atrial Fibrillation at University Hospital Basel: A Retrospective Study
NCT05542017
Atrial Fibrillation Prior and Post Elective Cardioversion
NCT05926401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The patients were divided into two groups - patients who remained in sinus rhythm (SR) (group 1) and patients with AF recurrence (group 2) after one month of follow-up.
Echocardiography: All patients underwent routine transthoracic echocardiography (TTE) prior to cardioversion and transoesophageal echocardiography (TEE) (EPIQ 7 Echocardiography Machine, Philips Ultrasound, Netherlands) to exclude left atrial and left atrial appendage thrombus. TTE was repeated in patients who remained in SR 24 hours after cardioversion. All standard measurements were taken from the parasternal long and short axes and apical two- and four-chamber windows. All assessments and measurements were made according to the American Society of Echocardiography (ASE) guidelines (10).
Left ventricular ejection fraction (LVEF) was calculated according to the modified biplane Simpson method (10). Mitral flow velocities were recorded from the apical four-chamber view with a sample volume of 5 mm placed at the level of the mitral valve tips using pulsed-wave Doppler (PWD). Peak early (E) and late (A) mitral entry velocities were recorded.
LAKE (left atrial kinetic energy) values were calculated at the 24th hour after cardioversion. LAKE was defined as 0.5 × left atrium stroke volume (cm³, volume at the beginning of left atrial systole - left atrium minimal volume) × 1.06 (g/cm³, blood density) × (peak A velocity)² (cm/sec, transmitral PWD A velocity) (8).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atrial fibrillation recurrence
Atrial fibrillation recurrence one month after cardioversion
Cardioversion
In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
Sinus rhythm continue
Sinus rhythm continue one month after cardioversion
Cardioversion
In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardioversion
In proper atrial fibrillation patients, cardioversion was performed to provide sinus rhythm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* underwent successful electrical cardioversion
* suitable for echocardiographic imaging
* who agreed to participate in the study
Exclusion Criteria
* previous valve surgery,
* severe left ventricular systolic dysfunction (ejection fraction \< 40%),
* severely dilated left atrium (\> 5 cm),
* previous ablation of atrial fibrillation, or paroxysmal atrial fibrillation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bursa Postgraduate Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan ARI
Professor Doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Bursa Postgraduate Hospital AF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.